PT-141
PT-141 (Bremelanotide / Vyleesi)
A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder (HSDD) in women. Acts centrally rather than on the vascular system.
PT-141 (bremelanotide) is FDA-approved as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. This page discusses the compound in a research context. The approved form is prescription-only and should be used under physician supervision. Research-grade PT-141 sold by compound vendors is not the same as the FDA-approved product and is not approved for human use in that form.
What it is
PT-141 (bremelanotide) is a synthetic peptide that acts as a non-selective melanocortin receptor agonist. It is a metabolite of Melanotan II and works through the central nervous system rather than directly on the vascular system — which distinguishes it mechanistically from PDE5 inhibitors like sildenafil.
Bremelanotide received FDA approval (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.
What research shows
- Improved sexual desire and arousal in women with HSDD (clinical trial data)
- Increased sexual function in men with erectile dysfunction in some trials
- Central nervous system mechanism — acts on brain pathways rather than directly on blood vessels
- Rapid onset (45–90 minutes post-injection)
What remains unknown
- Optimal dosing in men — most data is in women
- Long-term use effects
- Full side effect profile across populations (nausea and blood pressure changes are documented)
Administration basics
Common use cases
Sexual dysfunction, libido enhancement in both men and women.
Half-life
~2.7 hours.
Administration
Subcutaneous injection 45–90 minutes before sexual activity. FDA-approved version is a pre-filled autoinjector.
Research Protocols & Common Usage
Doses used in research
- FDA-approved dose is 1.75mg subcutaneously as needed (Vyleesi)
- Clinical trials studied doses from 0.5mg to 3mg
- Community protocols commonly report 0.5–2mg per use, starting low to assess response
Administration routes studied
Typical protocol duration
PT-141 is used on an as-needed basis, not as a daily protocol.
Common stacking protocols
- PT-141 + low-dose tadalafil — sometimes combined in community use; no formal research supports this combination
Contraindications & combinations to avoid
- Antihypertensive medications — PT-141 can elevate blood pressure
- Nitrates — significant cardiovascular interaction risk
- High cardiovascular risk — blood pressure elevation makes PT-141 unsuitable without physician clearance
- Should NOT be combined with Melanotan II — overlapping melanocortin receptor activity increases side effect risk
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with PT-141 and what to avoid.
Track your PT-141 protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the PT-141 page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.